US FDA amends cGMP regulations to prevent drug labelling errors
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a final rule that will allow drug manufacturers to use a broader range of "error prevention" and "labelling control" techniques than are permitted under the agency's current good manufacturing practice regulations for human and veterinary drug products1.